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Altered Blood Vessel Responses in the Eye and Finger
in Coronary Artery Disease
Rebekka Heitmar,1 Robert P. Cubbidge,1 Gregory Y. H. Lip,1,2 Doina Gherghel,1
and Andrew D. Blann2
PURPOSE. Cardiac function, such as heart rate variability, is
abnormal in coronary artery disease, but its relation with the
function of ocular and nail-fold blood vessels is unknown. The
hypothesis was that there is abnormal retinal and peripheral
microvascular endothelial function compared with large blood
vessel and cardiac function. Twenty-four patients with coro-
nary artery disease (CAD) and 30 healthy, age- and sex-matched
control subjects were enrolled in the study.
METHODS. Peripheral microcirculatory function was measured
with continuous retinal vessel diameter assessment and nail-
fold capillaroscopy. Systemic vascular function was evaluated
by 24-hour blood pressure, arterial stiffness, low (LF)- and high
(HF)-frequency heart rate variability, ECG monitoring, and the
plasma markers von Willebrand factor (vWf) and soluble E
selectin.
RESULTS. Peripheral nail-fold capillary (P  0.009) and retinal
vessel (average baseline corrected flicker response [BFR]; P 
0.034) responses and reaction time in response to flicker (P 
0.016) were significantly different in patients compared with
controls. Furthermore, patients demonstrated higher arterial
stiffness (P  0.005), LF and HF heart rate variability (P 
0.004, P 0.006), and vWf level (P 0.044), but there was no
difference in soluble E selectin level (P  0.278). In the CAD
patients, LF and HF heart rate variability both correlated with
average BFR (r  0.58, P  0.004; r  0.6, P  0.003,
respectively). There was no such relationship in the healthy
controls.
CONCLUSIONS. Microcirculatory abnormalities of the retina and
nail-fold vessels are present in CAD. The two indices of heart
rate variability correlated with an index of ocular vessel re-
sponses. The latter may be a surrogate marker of abnormal
heart rate variability in CAD. (Invest Ophthalmol Vis Sci. 2011;
52:6199–6205) DOI:10.1167/iovs.10-6628
Blood vessel tone is regulated both locally (for example, bythe production of endothelin and nitric oxide by the en-
dothelium) and centrally (by the effects of the autonomic
nervous system on medial smooth muscle cells).1,2 Commonly
used measures of vascular function and reactivity include sys-
tolic and diastolic blood pressure (SBP/DBP) at the brachial
artery and heart rate variability (HRV), as measured by electro-
cardiogram (ECG). Both indices are known to vary over a
24-hour period because of an alteration in the balance in
sympathetic and parasympathetic activity.3,4
The major pathophysiological drivers of atherosclerosis,
manifesting in the clinical setting as coronary artery disease
(CAD), include thrombosis and hypertension, and both of
these are related to endothelial dysfunction.5 Subjects with
CAD also display altered diurnal blood pressure cycling, re-
duced heart rate variability, and increased arterial stiffness.6–8
While these abnormalities are reflective of large artery disease,
there is also evidence of disturbance in small arteries and
arterioles, down to the level of the peripheral vascular beds
(i.e., the microcirculation),9,10 an example of which is retinal
disease, as is often present in diabetic and hypertensive reti-
nopathy.11,12 However, it is as yet unclear whether microcir-
culatory changes are contributors to, or sequelae of, the dis-
ease process.
Microcirculatory function can be assessed using techniques
such as laser Doppler flowmetry, tissue oximetry, nail-fold
capillaroscopy, and retinal vessel reactivity,13–16 and these may
be surrogates of systemic vascular disease.17–19 Noninvasive
retinal vessel analysis could be a useful tool, not only for early
diagnosis of ocular disease but also to assist diagnosis and for
monitoring of the progression of systemic vascular disease.18
Alterations of the ocular vessel wall and structure, both con-
junctival and retinal, can also occur and is detected by fundus
photography and conjunctival images.9 For example, ocular
vessel dysfunction has been demonstrated in diabetic patients
with CAD, as the spectral wave shape of the color Doppler
measurements at the retrobulbar vessels level exhibits a flat-
tening of the systolic phase.20
It is also known that large-artery stiffness is increased, not
only in hypertensive and prehypertensive patients, but also
in patients who have CAD,21–23 although to date no research
has assessed retinal vessel reactivity in patients with CAD.
Furthermore, other evidence of endothelial perturbation in
CAD comes from increased levels of the plasma markers von
Willebrand factor (vWf) and soluble E selectin.24 Nonethe-
less, new technologies assessing the ocular and nail-fold
circulation may determine functional abnormalities in the
function of a vascular bed that reflect pathologies in major
organs, such as the heart and the brain.25,26 As many large-
vessel vascular changes occur before the development of
CAD, such microcirculatory changes may also be predictive
of future systemic pathology.
We therefore hypothesized that subjects with established
CAD have altered indices of peripheral microcirculatory dis-
ease (e.g., nail-fold capillaroscopy and ocular vessel abnormal-
ities), when compared to healthy subjects, and that these
correlate with systemic indices such as heart rate variability
and blood pressure. We tested our hypothesis in a simple
case–control study.
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MATERIALS AND METHODS
Subjects
We recruited 24 patients with established CAD, proven by coronary
angiography, from a postmyocardial infarction cardiac rehabilitation
unit. Abnormal blood vessel physiology in this group was confirmed by
heart rate variability, large-artery stiffness, and the presence of the
plasma markers vWf and soluble E selectin. Age-matched, healthy
individuals were recruited from the patients’ spouses and other volun-
teers. Exclusion criteria were age18 years, connective tissue disease,
cancer, stroke, diabetes mellitus (DM), hypertension (HT: SBP/DBP 
140/90 mm Hg), atrial fibrillation (AF), stroke, history of ocular disease
(i.e., patients with a refractive error of more than 3 D spherical
equivalent and more than 1 D cylindrical equivalent; required to
address possible magnification/minification and so a cause of over- or
underestimation of the retinal diameter measured), or a history of
neurologic diseases associated with loss of visual function or any type
of ocular surgery. Approval was obtained from the West Birmingham
and Aston University ethics committees. Written informed consent was
received from all individuals taking part in the study. The study was
designed and conducted in accordance with the Declaration of Hel-
sinki.
Study Protocol
A full history and physical examination were conducted, to ensure that
the subjects were free of any disease, as outlined in the exclusion
criteria. All subjects were instructed to refrain from consuming caffein-
ated products, chocolate, and alcohol and from smoking on the study
day. In addition, they were asked to abstain from their usual medica-
tion 24 hours before the appointment, in an attempt to minimize the
effects of medication and in accordance with previous studies and with
practice in cardiovascular disease research.27 All subjects underwent
the test procedure outlined below.
Systemic Hemodynamic Parameters
Ambulatory Blood Pressure Monitoring. Twenty-four
hours of blood pressure and ECG data were collected from each
patient and control (Cardiotens-01; Meditech Ltd., Budapest, Hungary).
All subjects completed a diary giving information about any use of
medication (dosage and time) and physical activities (e.g., walking or
other rigorous exercise). Day and night periods were estimated based
on true sleep and wake-up times for each individual participating in the
study. SBPs and DBPs were used to obtain an ambulatory arterial
stiffness index (AASI), calculated according to the formula: AASI 1
slope of the regression fit of the DBP as a function of the SBP (using BP
recordings of a 24-hour monitoring time).28,29 The closer the value of
AASI to 1, the stiffer the arterial tree of a given subject.
Heart Rate Variability. HRV analysis assesses autonomic ner-
vous system (ANS) function by estimating sympathetic and parasym-
pathetic activity and can be analyzed in either time- or frequency-
domain analyses of ECG recordings: The latter was used as it focuses on
global variations.30 Recordings were Fourier transformed to obtain
power spectra, and from the result, two frequency ranges were as-
sessed: low frequency (LF, 0.04–0.15 Hz) and high frequency (HF,
0.15–0.40 Hz) (Cardiovision 1.7.2 software; PMS Instruments, Ltd.,
Maidenhead, UK). LF is mainly a measure of sympathetic activity with
a minor influence of parasympathetic activity, whereas HF represents
solely parasympathetic activity.31,32 Therefore, an LF/HF ratio mea-
sures sympathovagal balance, an increase of this ratio indicating a
predominance of the sympathetic versus parasympathetic nervous
system activity. Values for LF, HF, and LF/HF ratios were obtained from
the 24-hour ECG recordings and were extracted similarly to the BP
recordings for daytime and nighttime and circadian changes. Circadian
changes were calculated for each LF and HF and the LF/HF ratio of
each participant, by using the equation: Circadian change HRV 
active period HRV  passive period HRV.
Ocular Circulation
Intraocular Pressure. IOP was measured by contact tonome-
try and calculated as the mean of three consecutive readings after
instillation of 1 drop of 0.4% benoxinate hydrochloride (Chauvin Phar-
maceuticals Ltd., Kingston-on-Thames, UK, TonopenXL; Medtronic So-
lan, PMS Instruments, Maidenhead, UK). Data were discarded if the
coefficient of variation (CV) exceeded 5%.
Retrobulbar Blood Flow Velocities. The patient was posi-
tioned supine with the head on a pillow for the 15-minute acclimati-
zation period necessary to reach stable BP. Color Doppler ultrasound
was used to collect the following data: (1) Blood flow velocities were
measured in the ophthalmic artery (OA), central retinal artery (CRA),
and posterior ciliary arteries (PCAs; Acuson Sequoia; Siemens, New-
bury, UK).33 Peak systolic velocity (PSV), and end diastolic velocities
(EDVs) of each OA, CRA, and medial and temporal PCA were measured
on the recorded spectral pulse wave. Resistive indices (RIs) were
calculated according to RI  (PSV  EDV)/PSV. (2) The spectral wave
form of the blood flow velocities was measured in the OA and CRA.
Based on the appearance of the spectral wave, subjects were grouped
into normal or abnormal wave shape (i.e., a flattened systolic phase)
for both the OA and CRA.20 Figure 1 illustrates a normal and an
abnormal spectral wave shape: the former had a clear, sharp peak, and
the latter had a far smaller, rounded peak.
Dynamic and Static Retinal Vessel Assessment. After full
pupil dilation was obtained with 1% tropicamide (Chauvin Pharmaceu-
ticals, Ltd.), digital fundus images and reactivity parameters of retinal
blood arteries and veins were obtained (Retinal Vessel Analyzer [RVA];
Imedos Systems (UG), Jena, Germany).34 For static vessel analysis,
black-and-white fundus images were obtained at a 30° angle with the
optic nerve head centered, with the inbuilt fundus camera (model
450F; Carl Zeiss Meditec, GmbH, Oberkochen, Germany). Arterial and
venous diameters provided an arteriovenous ratio (AVR), central reti-
nal artery equivalent (CRAE), and central retinal vein equivalent
(CRVE) (Vesselmap software; Imedos Systems, UG).35,36 CRVE, CRAE,
and AVR were calculated from arteries and veins that were located
within a ring whose center was the optic nerve head and whose inner
and outer margins were of one-half disc diameter (DD) and one full
DD. These measurements (AVR, CRAE, and CRVE) are standard oph-
thalmic indices and are used to describe the physical structure of
different retinal arteries and veins, such as luminal diameter.
Static imaging was followed by dynamic assessment, where retinal
diameters were measured continuously at a sampling rate of 25 Hz.
Stimulation of retinal blood vessels was done by optoelectronic inter-
ruption of the green fundus illumination used by the RVA resulting in
a flickering light provocation with a 12.5-Hz frequency.37–39 After BP
stabilization and image focusing, a vessel segment of the superior
temporal retinal artery and vein (40 measurement units; 500 m in
length, according to the Gullstand model eye) was chosen at a distance
of 1.5 to 2 disc diameters away from the margins of the optic nerve
head. The baseline diameters of both the artery and vein were re-
corded according to the standard RVA protocol39 for 50 seconds,
followed by three cycles of 20-second flicker provocation, each with
80 seconds of recovery time. This resulted in a 350-second measuring
period during which the fellow eye was occluded. From the diameter
recordings, the values for maximum dilation (MD), maximum constric-
FIGURE 1. Spectral wave shape recorded by color Doppler ultra-
sound. Spectral wave shape of the ophthalmic artery of (top) a healthy
individual and (bottom) a subject with coronary artery disease. Vertical
axis: blood flow velocity (m/s), horizontal axis: time.
6200 Heitmar et al. IOVS, August 2011, Vol. 52, No. 9
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/16/2018
tion (MC), and dilation amplitude (DA), arterial baseline corrected
flicker response (BFR), and arterial and venous reaction time (RT) in
response to flicker provocation were calculated40 (Fig. 2).
Reproducibility measurements of dynamic retinal parameters in a
sample of 10 healthy controls showed good agreement between the
paired measurements. Interassay CV for retinal arteries were 4% for
baseline diameter, 7.3% for MD, 4.1% for MC, 3.7% for DA, 3.4% for BFR,
and 7.1% for arterial reaction time. Venous CVs showed similar results:
3.8% for baseline diameter, 4.6% for MD, 2.1% for MC, 4.6% for DA, and
4.7% for venous reaction time. Intra-assay CVs and other technical data
have been described in detail elsewhere.40
Peripheral Circulation
Capillaroscopy of the front row nail-fold capillaries was used to assess
peripheral microcirculation. It has been used to evaluate peripheral
vasospasm in patients with angina and other systemic vascular dis-
eases,41–43 An infrared laser beam is directed at the nail fold with a
fiber optic probe, and blood flow is determined from the measured
frequency Doppler shift. (CAM1 Laser Doppler Capillary Anemometer;
KK Technology, Devon, UK). Immediately before capillary flow was
measured, both hands of each subject were immersed in warm water
(40°C) for 3 minutes to maximize blood flow and to therefore mini-
mize any influence of seasonal temperature variations on flow vari-
ables.44–46 Data were collected according to the following procedure:
(1) Baseline measurement. After image focusing (front row capillaries
of the nail-fold area of the right-hand ring finger), a baseline measure-
ment of at least 30 seconds was obtained by means of laser Doppler
flowmetry to obtain baseline capillary flow (BCF). (2) Cold provoca-
tion with carbon dioxide. The nail-fold area was cooled immediately
after baseline data acquisition by rapidly decompressing carbon diox-
ide for 60 seconds. Stream temperature was calibrated at 15°C to
cool the nail-fold area down to 15°C.43 (3) Recovery time. This
period was defined as the time needed (in seconds) for capillary flow
to return to baseline values after cessation of cold provocation.
Plasma Markers
After the subjects fasted overnight and refrained from systemic medi-
cation, venous blood was collected into citric acid, and plasma was
obtained after centrifugation at 1000g for 20 minutes. Levels of von
Willebrand factor (vWf) and soluble E selectin were measured by
commercial enzyme-linked immunosorbent assay (ELISA; Dako-Cyto-
mation, Cambs, UK, and R&D Systems, Abingdon, UK). The ELISA’s
had intra- and interassay coefficients of variation 5% and 10%,
respectively.
Power Calculation
Our pilot data40 reported a significant difference in retinal vein diam-
eter in 21 smokers (mean  SD, 161  6 m) compared with 21 age-
and sex-matched nonsmokers (150 16 m; P 0.018). We therefore
based our present sample size on the hypothesis of a similar difference
(i.e., two thirds of an SD) in the retinal vein of patients with CAD. For
a 1   of 0.9 and   0.05, a sample size of 48 is required.
Accordingly, we recruited consecutive subjects to a sample size of at
least 24 per group. We recruited more controls (to n  30) for added
confidence. In addition, this sample size provides the power ( 0.05,
1    0.8) to detect a correlation coefficient (r) of 0.5.47
Statistical Analysis
Continuous data were subjected to the Shapiro-Wilks test, to determine
distribution. If normally distributed, they are presented as the mean
with SD, with the groups compared by t-test. Data distributed non-
normally are presented as the median with interquartile range (IQR),
analyzed by the Mann-Whitney U test. Categorical data were compared
using the 2 test. Serial data were analyzed by repeated-measures
analysis of variance or Friedman’s method. Data were correlated using
Pearson’s method (if normally distributed) or Spearman’s method (if
non-normally distributed). With multiple analyses, in simple intergroup
testing (see Tables 2, 3), we set a more stringent probability at P 0.01
for statistical significance. For data in Tables 4A and 4B, the analyses
were inherently more robust (repeated measures analysis of variance
and Friedman’s methods) and so we do not have to reduce the level of
probability from P  0.05 (Statistica ver. 6.0; Statsoft, Tulsa, OK).
RESULTS
Patient and controls were matched for age, sex, and blood
pressure, but the patients had a higher body mass index than
the controls (Table 1). The difference in proportions of men
and women (23% of controls are women, 12.5% of CAD pa-
tients are women) is not significant. We confirmed endothelial
abnormalities in patients with plasma markers and with assess-
ment of HRV and arterial stiffness. CAD patients had signifi-
FIGURE 2. Changes in a retinal vessel as it is stimulated by flickering
light. The horizontal axis is time (seconds). Left: BDF defines the
fluctuation in the baseline diameter. Middle: an increase is shown in
relative vessel diameter due to flickering light. This response provides
the MD, MC, DA, and the time to reach MD and MC. Right: the
responses of the vessel as it recovers.
TABLE 1. Clinical and Demographics
Parameter
Controls
(n  30)
CAD
(n  24) P
Sex, M/F 23/7 21/3 0.309
Age, y 53 (9) 56 (9) 0.162
BMI, kg/m2 26 (3) 28 (4) 0.023
SBP, mm Hg 120 (12) 121 (13) 0.938
DBP, mm Hg 75 (9) 73 (12) 0.883
Previous ACS — 24
CABG — 9
PCTA  Stent — 6
No intervention — 3
Aspirin — 20
Statins — 21
ACEIs — 17
Clopidogrel — 10
H2 receptor antagonists — 3
Ca channel antagonists — 5
Selective 1 blocker — 19
Other drugs (nicorandil, paroxetine,
alendronate, candesartan)
— 4
Data are presented as mean and standard deviation or as number
of patients. CABG, coronary artery bypass graft; PCTA, percutaneous
transluminal angioplasty; ACS, acute coronary syndrome; ACEIs, ang-
iotensin-converting enzyme inhibitors.
IOVS, August 2011, Vol. 52, No. 9 Ocular Blood Vessel Changes in Coronary Artery Disease 6201
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/16/2018
cantly increased vWF levels (88  15 IU/dL vs. 82  8 IU/dL;
P  0.044) but not soluble E selectin (55.2  12.7 ng/mL vs.
51.0  13.0 ng/mL; P  0.278) compared with healthy con-
trols. AASI was increased in CAD patients compared with the
controls, even though there were no differences in day, night,
or mean 24-hour BP (Table 2). HRV analysis using the 24-hour
ECG recordings showed no differences in the day or night LF
activity (reflecting sympathetic activity), or daytime HF activity
(reflecting parasympathetic activity) between the groups.
Nighttime HF activity was marginally lower in the patients.
There was an (expected) decline LF activity in the healthy
controls from day to night while HF activity increased,
whereas in the patients, neither change was present. Day
and night changes in LF, HF, and their ratio (a measure of
sympathovagal balance) were altered in the patients com-
pared with the controls. The controls had on average 7.8 
1.1 hours of sleep, whereas the patients had 7.9  1.1 hours
(P  0.604).
Table 3 shows ocular parameters. There were no differ-
ences in IOP, being 13  3 mm Hg in the controls versus 14 
4 in the patients (P 0.694). The retrobulbar blood velocity of
the OA, CRA, and CRV were comparable between the study
groups, but CRVE was higher in the patients. The dynamic
retinal vessel parameters are shown in Tables 4A (arteries) and
4B (veins). There were no significant differences in mean
arterial and venous diameters in the patients and controls. In
the arteries (Table 4A), continuous retinal diameter analysis
showed comparable results for MD, MC, and DA between the
study groups. Baseline corrected flicker response (BFR)
showed an altered reaction pattern in the dilatory response of
patients compared with controls. Furthermore, reaction time
to flicker stimulation was, despite a similar baseline reaction
time, significantly different between the groups, in that the
patients needed progressively longer for each stimulation cy-
cle, whereas the controls’ arterial reaction time was compara-
ble between cycles. All venous data were comparable between
the groups (Table 4B).
Spectral wave shape analysis of the OA and CRA revealed no
significant difference in the proportion of CAD patients with
flattened systolic phase in the OA (n  10 abnormal wave
shape, 14 normal) compared with the controls (6 abnormal, 24
normal; P 0.083). In the CRA, parallel data were 16 abnormal
wave shapes and 8 normal wave shapes in the patients, com-
pared with 7 abnormal and 23 normal wave shapes in the
controls (P  0.001). For illustration, Figure 1 shows the
spectral wave shape of the OA in a healthy person and a patient
with CAD.
Finger Blood Flow and Reactivity
Blood velocity in CAD patients needed considerably longer to
recover after cold provocation than in the controls (CAD me-
dian, 35; IQR, 15–50 seconds; controls, 21; 15–25 seconds; P
0.009). However, there was no difference in nail-fold capillary
blood velocity in the patients (BCF 0.18  0.06 mm/s) com-
pared with the controls 0.23  0.11 mm/s (P  0.064).
Correlations
We performed the Spearman correlation analyses to determine
any possible relationships between indices of vascular function
TABLE 2. Blood Pressure and Heart Rate Variability Parameters
Parameter Controls (n  30) Patients (n  24) P (between Groups)
24-h Blood Pressure
SBP/DBP day, mm Hg 125 (11)/76 (8) 120 (15)/73 (9) 0.381/0.369
SBP/DBP night, mm Hg 110 (10)/63 (7) 106 (14)/62 (9) 0.311/0.531
SBP/DBP 24h, mm Hg 120 (10)/72 (7) 117 (10)/68 (8) 0.469/0.114
AASI, AU 0.24 (0.09) 0.35 (0.15) 0.005
Heart Rate Variability from 24-h ECG
LF day, NU 75 (8) 70 (10) 0.067
LF night, NU 67 (13) 73 (10) 0.092
Within group 0.001 0.291
HF day, NU 23 (7) 26 (8) 0.205
HF night, NU 31 (12) 25 (9) 0.047
Within group 0.001 0.689
LF/HF night, NU 2.8 (1.4 to 3.6) 3.5 (2.2 to 4.5) 0.069
LF/HF day, NU 3.8 (2.8 to 4.1) 3.2 (2.1 to 3.9) 0.114
Within group 0.002 0.638
Day/night LF, NU 7.9 (0.0 to 13.0) 2.9 (13.0 to 6.0) 0.004
Day/night HF, NU 8.3 (14.0 to 2.0) 1.0 (7.0 to 9.0) 0.006
Day/night LF/HF, NU 1.0 (0.3 to 1.6) 0.3 (1.7 to 0.9) 0.027
Data presented as the mean (SD) or the mean (IQR), depending on distribution. AASI, Ambulatory
Arterial Stiffness Index; NU, normalized units.
TABLE 3. Ocular Parameters
Parameter
Controls
(n  30)
Patients
(n  24) P
Retrobulbar Blood Flow as Measured with Color Doppler
Ultrasound
OA (PSV), mm/s 36 (8) 40 (9) 0.107
(EDV), mm/s 9 (4) 0.76 (0.06) 0.654
CRA (PSV), mm/s 11 (3) 12 (3) 0.969
(EDV), mm/s 3.4 (2.5 to 4.1) 3.6 (2.2 to 4.7) 0.611
(RI) 0.70 (0.08) 0.68 (0.10) 0.622
CRV (Max), mm/s 6.4 (4.6 to 6.7) 7.3 (5.0 to 9.1) 0.275
(Min), mm/s 4.2 (2.9 to 4.5) 4.8 (3.3 to 5.3) 0.302
Static Retinal Vessel Measures Obtained by Retinal
Photography
AVR, ratio 0.85 (0.09) 0.83 (0.09) 0.923
CRAE, AU 193 (26) 201 (21) 0.331
CRVE, AU 232 (26) 251 (26) 0.041
Data presented in mean and standard deviation or mean and inter
quartile ranges depending on distribution. AU, arbitrary units.
6202 Heitmar et al. IOVS, August 2011, Vol. 52, No. 9
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/16/2018
in ophthalmic vessels and in nail-fold capillaries versus sys-
temic and cardiac indices. In the CAD patients, average retinal
artery BFR correlated with both circadian HF and LF heart rate
variability (r  0.58, P  0.004; r  0.6, P  0.003, respec-
tively). In the healthy controls, these indices failed to correlate
significantly (r  0.173, P  0.408; r  0.181, P  0.388,
respectively).
DISCUSSION
We present data on ocular blood vessels and capillary blood
flow in CAD, in addition to systemic hemodynamic indices and
plasma markers, compared with healthy age- and sex-matched
controls. The frequency of men and women in the study does
not reflect the normal distribution of the sexes in the healthy
population (i.e., 50/50), but is more reflective of CAD which is
more prevalent in men. The actual proportions of the sexes
reflect those in our cardiology clinics. We did not prospec-
tively favor either sex during the recruitment process. As
expected, the patients had adverse arterial stiffness, plasma
markers, and heart rate variability compared with the controls.
Our new findings are that the patient’s CRVs were larger than
those of the controls and that a higher proportion of the
patients’ CRAs showed abnormal spectral wave shape. Further-
more, the CAD patients had OAs (but not veins) that showed
abnormal reactivity to flicker light provocation and slower
reaction time. Although there was no difference in the velocity
of nail-fold capillary blood flow in the patients compared with
the controls, the patients had blood vessels that needed con-
siderably longer to recover blood flow after cold provocation.
The average retinal artery responses to flickering light corre-
lated with LF and HF heart rate variability, in a positive (r 
0.58) and inverse (r  0.6) manner. That these indices
correlate suggests that the abnormalities in our patients’ heart
rate variability (possibly driven by dysfunctional autonomic
nervous system processes) was related to the abnormal re-
sponses of ocular arteries. Whether this relationship is patho-
physiological, we cannot say.
Pressler et al.48 recently compared ocular vessel indices in
patients with cardiovascular disease. In their cases with aortic
coarctation and high blood pressure, retinal arteriolar vessel
diameter (but not venous diameter) was significantly reduced
compared with that in controls. No differences in dynamic
retinal responses were found, although their analyses were
based on averaged responses. Unlike them, we were unable to
find any significant correlations between any of our research
indices and body mass index (BMI), although all our patients
had CAD, did not have high blood pressure, and were older
with a higher BMI than those of Pressler et al. Traditionally,
large-artery assessments have been used for the assessment of
vascular function. However, many of these tests are invasive,
have poor reproducibility, and are not informative regarding
the microcirculation. Instead, the eyes and nail-folds are con-
venient locations for noninvasive assessment of structural and
functional assessment of the microcirculation in several cardio-
vascular disorders.9,17–41 The eye itself is very vulnerable to
minor changes in perfusion, leading to structural and func-
tional abnormalities.49 It is therefore a suitable site to investi-
gate early changes that may predict large vessel disease.18
Our CAD patients were free of DM and HT and were all well
motivated to attend a rehabilitation course. However, most
patients received vasculoactive treatments that could have
masked structural vessel changes. In common with other stud-
ies, our patient group showed increased BMI and retinal ve-
nous diameter.50 Functional and structural changes are not
necessarily concurrent, although vasculature that appears to be
structurally normal can have functional impairment.51. Further-
more, static retinal diameter measurements can show varia-
tions of up to 34% which arise due to observer variability and
the particular stage of cardiac cycle in which they were
taken.52 When ocular vessel diameters are measured continu-
TABLE 4. Dynamic Retinal Vessel Diameters
A. Arterial Response
Parameter Controls (n  30) Patients (n  24) P
Size artery, AU 114 (18) 118 (16) 0.471
MD, %
F1 5.8 (2.9 to 7.1) 5.9 (3.0 to 8.4) 0.499
F2 6.0 (3.7 to 8.0) 4.9 (2.3 to 6.5)
F3 6.0 (4.4 to 6.1) 5.7 (3.1 to 6.9)
Intergroup P 0.472 0.165
MC, %
F1 2.5 (4.3 to 0.6) 2.6 (3.3 to 1.4) 0.148
F2 2.4 (3.5 to 1.5) 1.8 (2.6 to 1.0)
F3 1.8 (2.9 to 0.6) 2.2 (3.3 to 0.8)
Intergroup P 0.060 0.229
DA, %
F1 8.4 (4.4 to 11.8) 8.2 (4.9 to 12.1) 0.305
F2 8.4 (5.4 to 9.8) 6.7 (3.7 to 9.6)
F3 7.8 (5.5 to 9.7) 7.9 (4.6 to 10.6)
Intergroup P 0.779 0.064
BFR, %
F1 4.3 (1.6 to 6.4) 3.7 (1.0 to 5.5) 0.607
F2 4.4 (2.2 to 6.0) 2.9 (0.1 to 4.7) 0.194
F3 4.0 (2.1 to 5.1) 3.3 (0.4 to 5.8) 0.430
Intergroup P 0.564 0.034
RT, s
F1 17 (13 to 21) 16 (11 to 21) 0.100
F2 17 (14 to 21) 19 (13 to 22)
F3 18 (13 to 22) 22 (15 to 25)
Intergroup P 0.568 0.016
CT, s
F1 41 (35 to 45) 47 (40 to 53) 0.017
F2 42 (35 to 46) 52 (40 to 56) 0.010
F3 42 (38 to 48) 54 (38 to 61) 0.023
Intergroup P 0.688 0.275
B. Venous Response
Parameter Controls (n  30) Patients (n  24) P
Size vein, AU 147 (17) 156 (22) 0.061
MD, %
F1 6.3 (4.2 to 8.4) 5.0 (3.8 to 5.6) 0.168
F2 5.7 (4.4 to 7.1) 5.4 (3.9 to 6.8)
F3 6.1 (4.7 to 7.2) 5.6 (5.4 to 6.5)
Intergroup P 0.954 0.954
MC, %
F1 1.4 (2.0 to 0.6) 1.5 (2.4 to 0.5) 0.841
F2 1.7 (2.2 to 0.8) 1.7 (2.2 to 0.9)
F3 1.1 (1.8 to 0.5) 1.5 (2.1 to 0.4)
Intergroup P 0.367 0.368
DA, %
F1 7.7 (4.9 to 9.4) 6.4 (4.7 to 7.7) 0.285
F2 7.4 (5.2 to 8.8) 7.1 (5.8 to 8.4)
F3 7.2 (5.5 to 8.5) 7.1 (5.9 to 7.9)
Intergroup P 0.263 0.264
RT, s
F1 20 (18 to 22) 21 (14 to 24) 0.374
F2 19 (17 to 21) 20 (17 to 24)
F3 18 (15 to 21) 21 (17 to 24)
Intergroup P 0.142 0.896
P values for arterial response are by ANOVA and for venous
response are by ANOVA and Tukey. Data are presented as the mean
(IQR). All data are shown as percentage of change compared with the
corresponding baseline diameter. F1/F2/F3, flicker 1/flicker 2/flicker 3
(representing the three flicker cycles).
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ously, these limitations can be addressed. In addition our data
show that although the structure of retinal arteries seemed to
be comparable between the groups, the functional aspects are
already altered in the CAD group. The retinal arterioles of the
CAD patients showed a significant decrease in the reaction
pattern, which manifested as diminished dilatory response
with gradually longer reaction times with each flicker cycle.
The time needed to reach MC was also increased in the CAD
patients compared with the controls. The arteriosclerotic ves-
sel wall changes causing an overall stiffening alongside an
imbalance of local regulatory factors such as endothelin 1 and
nitric oxide are the factors most likely to contribute to an increase
in reaction and constriction time of retinal arterioles in CAD
patients. These results (in combination with their imbalance in
ANS function showing sympathetic overdrive and increased levels
of plasma markers) show systemic endothelial dysfunction, not
only at the large artery level but simultaneously at the microcir-
culatory vascular beds in different parts of the body. The absence
of any correlation between nail-fold and ocular circulation indices
in health or in CAD supports the view that both vascular systems
operate independently. Indeed, the fact that none of our other
research or routine indices correlated with the abnormal nail-fold
capillary responses in CAD implies the presence of an alternative
pathophysiological mechanism.
Our data are limited by the possible effects of various
systemic medications being taken by the patients and that we
recruited from a well-motivated group that may contribute to a
better than expected endothelial function compared with
poorly motivated patients on different medications. However,
similar to other studies27 we attempted to minimize the effect
of medication by discontinuing it for 24 hours, Nevertheless,
our patients had documented CAD, and we have demonstrated
their endothelial, blood pressure, and heart rate abnormalities.
We conclude that assessment of the retina may be a useful
tool in diagnosis of cardiovascular disease, as well as in moni-
toring disease progression and the efficacy of treatment.
The comparison of the presented results may be limited,
since the RVA data analysis was not standardized across re-
search groups.
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